Literature DB >> 8048816

Once daily antibiotic regimen in paediatric oncology.

E Bouffet1, C Fuhrmann, D Frappaz, D Couillioud, V Artiges, C Charra, D Bouhour, M Brunat Mentigny.   

Abstract

The feasibility and efficacy of a once daily antibiotic regimen were assessed in children with malignant tumours. Over a 44 month period, 296 febrile episodes were treated with a regimen of once daily ceftriaxone-amikacin (and teicoplanin or vancomycin if the patient had a central line). The treatment was successful in 272 (92%) episodes without modification of the antibiotic regimen, and only one patient died of uncontrolled sepsis. A once daily antibiotic regimen is therefore feasible and worthwhile in the treatment of febrile episodes in children with cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8048816      PMCID: PMC1029865          DOI: 10.1136/adc.70.6.484

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  21 in total

1.  Empiric antibacterial therapy in granulocytopenia induced by cancer chemotherapy.

Authors:  R H Rubin
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

2.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.

Authors:  M Rubin; J W Hathorn; D Marshall; J Gress; S M Steinberg; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

3.  Pharmacokinetics of teicoplanin in man after intravenous administration.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

4.  Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients.

Authors:  B S Kramer; R Ramphal; K H Rand
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.

Authors:  P A Pizzo; J W Hathorn; J Hiemenz; M Browne; J Commers; D Cotton; J Gress; D Longo; D Marshall; J McKnight
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

Review 6.  After empiric therapy: what to do until the granulocyte comes back.

Authors:  P A Pizzo
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 7.  Pharmacokinetic profile of ceftriaxone in man.

Authors:  I H Patel; S A Kaplan
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

Review 8.  Pharmacokinetic evaluation of single daily dose amikacin.

Authors:  P Van der Auwera
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

9.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

Authors:  S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

10.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

View more
  3 in total

1.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.

Authors:  R J Tomlinson; M Ronghe; C Goodbourne; C Price; J S Lilleyman; S Das; V Saha
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

3.  Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients.

Authors:  Donna M Kraus; Manjunath P Pai; Keith A Rodvold
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.